Aimei Health Discloses Going Concern Doubt, Significant Redemptions, and Internal Control Weaknesses in Delayed Annual Report

summarizeSummary

Aimei Health's delayed annual report reveals a going concern warning, massive share redemptions, and material internal control weaknesses, alongside ongoing uncertainty for its proposed merger.

check_boxKey Events

• Going Concern Doubt Disclosed

  Management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern, citing the need to complete a business combination within a prescribed period or face liquidation.

• Significant Share Redemptions

  In 2025, 5,859,668 ordinary shares were redeemed for approximately $65.33 million, significantly depleting the Trust Account from $73.78 million in 2024 to $12.10 million by December 31, 2025.

• Material Weakness in Internal Controls

  Management determined that internal control over financial reporting was not effective as of December 31, 2025, due to inadequate segregation of duties and insufficient written policies and procedures.

• Business Combination Remains Pending

  The proposed merger with United Hydrogen is still awaiting required approvals from the China Securities Regulatory Commission (CSRC), with review ongoing since August 2024 and multiple requests for supplementary materials.

auto_awesomeAnalysis

Aimei Health Technology Co., Ltd. has filed its delayed annual report, revealing substantial doubt about its ability to continue as a going concern. This critical disclosure is compounded by significant share redemptions totaling $65.33 million in 2025, which drastically reduced the company's Trust Account balance. Furthermore, management identified a material weakness in internal controls over financial reporting due to inadequate segregation of duties and insufficient policies. The proposed business combination with United Hydrogen remains uncertain, pending crucial CSRC approvals that have been under review since August 2024 and have required multiple supplementary submissions. These factors collectively paint a precarious financial and operational picture for the SPAC, indicating high risk and uncertainty for investors.